Narwhal Capital Management grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,016 shares of the company’s stock after acquiring an additional 2,150 shares during the period. Johnson & Johnson comprises approximately 1.3% of Narwhal Capital Management’s holdings, making the stock its 21st biggest holding. Narwhal Capital Management’s holdings in Johnson & Johnson were worth $14,464,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $49,000. Advisory Alpha LLC boosted its holdings in Johnson & Johnson by 6.8% in the second quarter. Advisory Alpha LLC now owns 5,743 shares of the company’s stock valued at $839,000 after purchasing an additional 367 shares during the last quarter. Birmingham Capital Management Co. Inc. AL grew its stake in Johnson & Johnson by 4.0% during the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 43,076 shares of the company’s stock valued at $6,296,000 after purchasing an additional 1,644 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $283,000. Finally, Brown Financial Advisors acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $1,973,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $151.27 on Thursday. The business has a 50 day simple moving average of $147.76 and a 200 day simple moving average of $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $364.20 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.
Insider Buying and Selling
In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on JNJ shares. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $170.44.
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
- Five stocks we like better than Johnson & Johnson
- What is the Hang Seng index?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Invest in the FAANG Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Options Trading – Understanding Strike Price
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.